Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour.
cystectomy
exosomes
extracellular vesicles
neoadjuvant therapy
proteomics
urinary bladder neoplasms
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jun 2021
29 Jun 2021
Historique:
received:
07
05
2021
revised:
23
06
2021
accepted:
25
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Invasive urothelial bladder cancer (UBC) has high recurrence rates even after radical cystectomy (RC). Exosomes are membrane-bound nanovesicles, which have been shown to contribute to carcinogenesis and metastasis. We previously showed that urinary exosomes display a malignant profile in UBC patients despite the absence of detectable tumour. Here, we investigated exosomes from sampling sites close to or distant from the former tumour, aiming to understand the effect of the tumour on the local milieu. Ten patients scheduled for cystectomy after transurethral bladder resection (TUR-B), without remaining detectable tumour, were included. Exosomes were isolated from tissue explants of both the previous tumour site and distant bladder tissue. Proteins were quantified by mass spectrometry in seven patients. Exosomes from the previous tumour site were enriched in inflammatory but not cancer-related pathways compared to distant tissue. However, the 69 most abundant proteins in tissue-derived exosomes regardless of site, 20 of which were also found in urinary exosomes from our previous study, were enriched for cancer-related metabolic pathways and associated with poor prognosis in an external mRNA dataset. The enrichment of cancer-related pathways in the most abundant proteins, regardless of sampling site, confirms our hypothesis that despite the absence of detectable tumour, the entire bladder releases exosomes that contribute to metastasis and highlights the need for early RC.
Identifiants
pubmed: 34209558
pii: cancers13133242
doi: 10.3390/cancers13133242
pmc: PMC8267924
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Vetenskapsrådet
ID : 2018-02806
Organisme : Cancerfonden
ID : CAN 2016/469
Organisme : Radiumhemmets Forskningsfonder
ID : 181103
Organisme : Stockholms Läns Landsting
ID : 20140405
Organisme : Hjärt-Lungfonden
ID : 20140497, 20140711, 20130551, 20170543, 20190509, 20200646
Organisme : The KID grant of the Karolinska Institutet
ID : 2-5586/2017, 2-6144/2019
Organisme : Insamlingsstiftelsen Cancer- och Allergifonden
ID : 2017:107. 2021:10120
Organisme : • Swedish Research Council funding for clinical research in medicine (ALF) in Västerbotten, VLL
ID : Bas-ALF/VLL RV-848051
Références
Curr Protoc Immunol. 2016 Nov 1;115:14.42.1-14.42.21
pubmed: 27801511
Cancer. 2013 Sep 1;119(17):3219-27
pubmed: 23737352
Cancers (Basel). 2019 Jun 22;11(6):
pubmed: 31234517
Urology. 2000 Mar;55(3):368-71
pubmed: 10699612
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Cancers (Basel). 2020 Mar 12;12(3):
pubmed: 32178479
BMC Cancer. 2004 Oct 07;4:73
pubmed: 15471548
Cancer Sci. 2014 Jan;105(1):1-8
pubmed: 24168081
BJU Int. 2011 Sep;108(5):687-92
pubmed: 21087453
Eur Urol. 2012 Jun;61(6):1229-38
pubmed: 22189383
Cell. 2017 Oct 19;171(3):540-556.e25
pubmed: 28988769
Cancers (Basel). 2020 May 29;12(6):
pubmed: 32485907
Diagnostics (Basel). 2020 Jan 13;10(1):
pubmed: 31941070
J Cancer. 2019 Aug 28;10(21):5153-5161
pubmed: 31602268
Sci Rep. 2020 Apr 6;10(1):5960
pubmed: 32249794
Anticancer Res. 2010 Sep;30(9):3747-57
pubmed: 20944164
Clin Cancer Res. 2005 Feb 1;11(3):1010-20
pubmed: 15709166
Cell Mol Immunol. 2019 Jan;16(1):40-52
pubmed: 30275538
Int J Mol Sci. 2019 Mar 14;20(6):
pubmed: 30875722
Int Immunol. 2005 Jul;17(7):879-87
pubmed: 15908444
Front Immunol. 2019 Jul 17;10:1654
pubmed: 31379850
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Int J Mol Sci. 2019 Feb 14;20(4):
pubmed: 30769831
J Biol Chem. 2019 Mar 1;294(9):3207-3218
pubmed: 30593508
J Immunol. 2007 Aug 1;179(3):1969-78
pubmed: 17641064
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
Oncol Lett. 2018 May;15(5):6519-6526
pubmed: 29725402
J Transl Med. 2011 Jan 14;9:9
pubmed: 21235781
PLoS One. 2014 Dec 12;9(12):e115170
pubmed: 25502753
Front Immunol. 2019 Oct 31;10:2557
pubmed: 31736972
Cell. 2020 Aug 20;182(4):1044-1061.e18
pubmed: 32795414
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
J Immunol. 2010 Jan 15;184(2):902-11
pubmed: 20008292
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13368-73
pubmed: 15326289
J Urol. 2014 Aug;192(2):583-92
pubmed: 24530986